NervGen Pharma Corp.
TSXV NGEN.V
NervGen Pharma Corp. Price to Book Ratio (P/B) on January 14, 2025
-
NervGen Pharma Corp. 52-week high Price to Book Ratio (P/B) is NA on January 14, 2025, which is NA below the current Price to Book Ratio (P/B).
-
NervGen Pharma Corp. 52-week low Price to Book Ratio (P/B) is NA on January 14, 2025, which is NA below the current Price to Book Ratio (P/B).
-
NervGen Pharma Corp. average Price to Book Ratio (P/B) for the last 52 weeks is NA.
| Date | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield | Price to Earnings Ratio (P/E) |
|---|
| CEO | Mr. Michael Kelly |
| IPO Date | March 15, 2019 |
| Location | Canada |
| Headquarters | 2955 Virtual Way |
| Employees | 11 |
| Sector | Health Care |
| Industries | |
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.
Past 5 years
USD 0.91
StockViz Staff
January 15, 2025
Any question? Send us an email